Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: Results of a phase I/II study

International Journal of Gynecological Cancer

Volumn 16, Issue 4, 2006, Pages 1522-1528

  Marth, C ^a   Windbichler, G H ^a   Hausmaninger, H ^b   Petru, E ^c   Estermann, K ^a   Pelzer, A ^a   Mueller Holzner, E ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b St Johanns Spital   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Carboplatin; Interferon ; Ovarian cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; GAMMA INTERFERON; PACLITAXEL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HAIR LOSS; HEART ARRHYTHMIA; HUMAN; INFECTION; LEUKOPENIA; MOOD CHANGE; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SAMPLE SIZE; STOMATITIS; TASTE DISORDER; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; INTERFERON TYPE II; INTERFERON-GAMMA; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33745938818     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00622.x     Document Type: Article

References (24)

1. Chi DS, Sabbatini P. Advanced ovarian cancer. Curr Treat Options Oncol 2000;1:139-46.
2. Harries M, Kaye SB. Recent advances in the treatment of epithelial ovarian cancer. Expert Opin Investig Drugs 2001;10:1715-24.
3. Kirby TO, Huh W, Alvarez R. Immunotherapy of ovarian cancer. Expert Opin Biol Ther 2002;2:409-17.
4. Hwu P, Freedman RS. The immunotherapy of patients with ovarian cancer. J Immunother 2002;25:189-201.
5. Bookman MA. Biological therapy of ovarian cancer: current directions. Semin Oncol 1998;25:381-96.
6. Marth C, Fiegl H, Zeimet AG et al. Interferon-γ expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004;191:1598-605.
7. Zhang L, Conejo-Garcia JR, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348:203-13.
8. Meng RD, El-Deiry WS. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp Cell Res 2001;262:154-69.
9. Marth C, Helmberg M, Mayer I, Fuith LC, Daxenbichler G, Dapunt O. Effects of biological response modifiers on ovarian carcinoma cell lines. Anticancer Res 1989;9:461-8.
10. Clark S, McGuckin MA, Hurst T, Ward BG. Effect of interferon gamma and tumour necrosis factor alpha on sensitivity to cisplatin in ovarian carcinoma cell lines. Cancer Immunol Immunother 1994;39:100-4.
11. Nehme A, Julia AM, Jozan S, Chevreau C, Bugat R, Canal P. Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines. Eur J Cancer 1994;30A:520-5.
12. Windbichler GH, Hausmaninger H, Stummvoll W et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomised phase III trial. Br J Cancer 2000;82:1138-44.
13. D'Acquisto R, Markman M, Hakes T, Rubin S, Hoskins W, Lewis JL. A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma. J Clin Oncol 1988;6:689-95.
14. Pujade-Lauraine E, Guastalla JP, Colombo N et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996;14:343-50.
15. Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
16. Berek JS. Interferon plus chemotherapy for primary treatment of ovarian cancer, commentary. Lancet 2000;356:6-7.
17. Covens A, Carey M, Bryson P, Verma S, Fung Kee Fung M, Johnston M. Systematic review of first-line chemotherapy for newly diagnosed postoperative patients with stage II, III, or IV epithelial ovarian cancer. Gynecol Oncol 2002;85:71-80.
18. Muggia FM, Braly PS, Brady MF et al. Phase III randomised study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynaecologic oncology group study. J Clin Oncol 2000;18:106-15.
19. International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
20. WHO Handbook for reporting results of cancer treatment, No 48. Geneva, Switzerland: World Health Organisation Offset Publication, 1979.
21. Rustin GJS, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. J Clin Oncol 1996;14:1545-51.
22. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D et al. Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310-6.
23. Marth C, Weger A, Müller-Holzner E et al. The prognostic value of nuclear roundness and neopterin in ovarian cancer. Eur J Cancer 1993;29A:1863-8.
24. Marth C, Müller-Holzner E, Greiter E et al. Gamma-interferon reduces expression of the protooncogene c-erbB-2 in human ovarian carcinoma cells. Cancer Res 1990;50:7037-41.